Price
No data yet.
Social Signal Score
Analyst Ratings
2 analystsRevenue
$3.89M+388.08%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Jennifer Lynne Bath
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 76
- Beta
- 0.78
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -10.53
Financials
Revenue
$3.89M+388.1%Net Income
$-6.18M-6209.1%EBITDA
$-5.95M-4762.1%Free Cash Flow
$-4.18M-56418.0%EPS (diluted)
$-0.13-356.9%Shares Outstanding (diluted)
46.81M+2241.4%Operating Expenses
$8.51MCash & Debt
$7.63MReturn of Capital
$0.00Revenue by Segment (annual)
$15.41MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $15.32M | $-13.74M | $-0.30 |
| 2025 | $24.52M | $-30.23M | $-0.90 |
| 2024 | $24.52M | $-26.11M | $-1.03 |
| 2023 | $20.66M | $-26.56M | $-1.07 |
| 2022 | $19.36M | $-16.71M | $-0.87 |
| 2021 | $17.91M | $-7.34M | $-0.45 |
| 2020 | $14.72M | $-5.18M | $-0.36 |
| 2019 | $10.93M | $-7.62M | $-0.61 |
| 2018 | $5.44M | $-5.17M | $-0.57 |
| 2017 | $2.63M | $-5.38M | $-1.36 |
| 2016 | $1.90M | $151.0K | $0.10 |
| 2015 | $0.00 | $-62.5K | $-0.11 |
| 2014 | $0.00 | $68.0K | $0.11 |
| 2013 | $0.00 | $-95.6K | $-0.18 |
Valuation
HYFThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
70-50.00%Social Signal Score
Mentions (7)
- Newsbusinesswire.com·31d ago·Positive
MindWalk Holdings Corp. Announces Leadership Update AUSTIN, Texas--(BUSINESS WIRE)---- $HYFT #ai--MindWalk Holdings Corp. ("MindWalk") (NASDAQ: HYFT), a Bio-Native AI company, today announced that Thomas Lynch, PhD, has departed the company and ceased to serve as Chief Business Officer, effective October 16, 2026. "We thank Thomas for his contributions to MindWalk and wish him well," said Jennifer Bath, PhD, Chief Executive Officer and President of MindWalk. "Our commercial priorities do not cha…
View source ↗ - Newsbusinesswire.com·39d ago·Neutral
MindWalk Holdings Corp. Strengthens Boston-Based Development Leadership as Pipeline Advances Toward Preclinical Efficacy Studies BOSTON--(BUSINESS WIRE)---- $HYFT #ai--MindWalk Holdings Corp. (NASDAQ: HYFT) (“MindWalk” or the “Company”), a Bio-Native AI company, today announced three senior appointments that strengthen its Boston-based development leadership as the Company's pipeline advances toward preclinical efficacy studies. Zachary Maben, PhD, joins as Director, Antigen Discovery & Protein …
View source ↗ - Newsbusinesswire.com·47d ago·Neutral
MindWalk (NASDAQ: HYFT): Enterprise AI Has Found Its Ontology Layer. Biology Needs One Grounded in Biological Function AUSTIN, Texas--(BUSINESS WIRE)---- $HYFT #ai--MindWalk Holdings Corp. ("MindWalk") (NASDAQ: HYFT), a Bio-Native AI company, today outlined why the ontology layer now being built across enterprise AI does not reach biological function, and why life sciences requires a biological context layer of its own. ReefIQ™, MindWalk's biological context layer for life sciences, supplies wha…
View source ↗ - Newsseekingalpha.com·69d ago·Positive
MindWalk Holdings Corp. (HYFT) Q1 2027 Earnings Call Transcript MindWalk Holdings Corp. (HYFT) Q1 2027 Earnings Call Transcript
View source ↗ - Newszacks.com·69d ago·Negative
MindWalk Holdings Corp. (HYFT) Reports Q1 Loss, Misses Revenue Estimates MindWalk Holdings Corp. (HYFT) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to a loss of $0.07 per share a year ago.
View source ↗ - Newsmarketbeat.com·69d ago·Negative
MindWalk Q1 Earnings Call Highlights MindWalk NASDAQ: HYFT reported first-quarter fiscal 2027 revenue of CAD 3.8 million, up 21% from CAD 3.2 million a year earlier, as the company continued investing in commercialization of its ReefIQ biological-data platform and expanded its drug discovery partnership model.
View source ↗ - Newsbusinesswire.com·69d ago·Neutral
MindWalk Reports 21% Revenue Growth and Gross Margin Expansion to 59% in Fiscal First Quarter 2027 AUSTIN, Texas--(BUSINESS WIRE)---- $HYFT #ai--MindWalk Holdings Corp. ("MindWalk") (NASDAQ: HYFT), a Bio-Native AI company, today reported financial results for its fiscal 2027 first quarter ended July 31, 2026. The quarter marked the commercial launch of ReefIQ™, MindWalk's data platform, and the start of its shift toward recurring, platform-based revenue. Revenue increased 21.3% year over year to…
View source ↗
Earnings
Mon, Dec 21(in 4 weeks)
Consensus estimate $-0.05 per share
Typical surprise -64.7% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Sep 14$-0.09 vs $-0.05miss
- Wed, Jul 22$-0.06 vs $-0.05miss
- Thu, Mar 12$-0.06 vs $-0.04miss
- Mon, Dec 15$-0.05 vs $-0.01miss
- Mon, Sep 15$-0.07 vs $-0.04miss
- Tue, Jul 29$-0.04 vs $-0.02miss
Estimates and results for HYFT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by HYFT officers and directors.
No open-market trades in the recent filings. All 22 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
22 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in HYFT.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
